Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Increase in Short Interest

Posted by Stacy Sanders on Nov 13th, 2026

Senti Biosciences, Inc. (NASDAQ:SNTI – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 1,115,310 shares, a growth of 160.9% from the October 15th total of 427,404 shares. Approximately 3.7% of the company’s shares are sold short. Based on an average daily trading volume, of 15,911,284 shares, the short-interest ratio is currently 0.1 days.

Senti Biosciences Trading Down 1.4%

Shares of SNTI traded down $0.00 on Friday, reaching $0.14. 25,585 shares of the company’s stock were exchanged, compared to its average volume of 1,192,043. The stock has a market capitalization of $4.52 million, a P/E ratio of -0.08 and a beta of 2.31. The business has a 50 day moving average price of $0.26 and a two-hundred day moving average price of $0.68. Senti Biosciences has a 12 month low of $0.14 and a 12 month high of $2.88.

Senti Biosciences (NASDAQ:SNTI – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.08). The company had revenue of $0.02 million for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Senti Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

View Our Latest Report on SNTI

Senti Biosciences Company Profile

(Get Free Report)

Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.